ramipril / Generic mfg. - LARVOL DELTA

NT-proBNP in the Early Convalescent Phase after High-Risk Myocardial Infarction Is Associated with Adverse Cardiovascular Outcomes: the PARADISE-MI Trial. (PubMed, J Card Fail) - "Patients with elevated NT-proBNP concentrations approximately two weeks after a high-risk MI are at heightened risk of incident HF, recurrent coronary events and death, independent of baseline NT-proBNP concentrations and clinical characteristics. Elevations in NT-proBNP concentrations in the early convalescent phase may assist in risk stratification and identification of patients in need for more advanced preventive treatment approaches."

Journal • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Heart Failure • Myocardial Infarction

Layer-by-Layer Engineering of Black Seed Oil Based SNEDDSs (BSO-SNEDDSs): Optimizing Chemical Stability and Bioavailability in Ramipril Formulations. (PubMed, Int J Nanomedicine) - "While liquid SNEDDSs exhibit promisingly greater oral bioavailability than crystalline drugs do, the performance of multilayer solid SNEDDSs necessitates further refinement. Nonetheless, this comprehensive investigation establishes a robust foundation for continued research on multifunctional bioactive oil-based SNEDDSs to enhance the bioavailability of drugs with limited water solubility."

Journal • Cardiovascular • Hypertension

Optimizing hypertension management: the impact of drug class, socioeconomic factors, and simplified regimens on medication adherence. VATAHTA study. (PubMed, J Hypertens) - "Simplified regimens, particularly fixed-dose combinations, and the selection of drugs with favourable adherence profiles, like beta-blockers and potassium-sparing diuretics, can improve adherence. Addressing socioeconomic barriers should also be prioritized."

Journal • Cardiovascular • Hypertension • Myocardial Infarction

STAMI-BAS: STunning in Acute Myocardial Infarction - BAS (clinicaltrials.gov) - P4 | N=120 | Recruiting | Sponsor: Vastra Gotaland Region | Not yet recruiting ➔ Recruiting | Initiation date: Sep 2024 ➔ Jan 2025

Enrollment open • Trial initiation date • Cardiovascular • Myocardial Infarction • TNNI3

CLIgAN: Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy. (clinicaltrials.gov) - P4 | N=878 | Recruiting | Sponsor: Fondazione Schena | Trial completion date: Dec 2026 ➔ Dec 2028 | Trial primary completion date: Jun 2024 ➔ Jun 2026

Trial completion date • Trial primary completion date • Glomerulonephritis • IgA Nephropathy • Lupus Nephritis • Nephrology • Renal Disease

Systematic Review of Management Strategies for Alport Syndrome: Implications for Male Patients. (PubMed, Health Sci Rep) - "Key interventions examined included bardoxolone methyl, ramipril, and losartan. The protocol for this systematic review is registered in the Open Science Framework (OSF): osf. io/k86ms."

Journal • Review • Genetic Disorders • Nephrology • Otorhinolaryngology • Renal Disease

Comprehensive investigation of Prunus armeniaca for natural green synthesis of carbon quantum dots; Applications as fluorescent nano-probes for ramipril. (PubMed, Talanta) - "Furthermore, the storage stability (in refrigerator) and reusability of the proposed CQDs were effectively confirmed for RAL analysis for 10 weeks. The proposed tool was finally compared to some other reported techniques and was found to be more efficient and cost-effective."

Journal

WF-1801: Testing Ramipril to Prevent Memory Loss in People With Glioblastoma (clinicaltrials.gov) - P2 | N=75 | Completed | Sponsor: Wake Forest University Health Sciences | Active, not recruiting ➔ Completed

Trial completion • Brain Cancer • CNS Tumor • Cognitive Disorders • Glioblastoma • Oncology • Solid Tumor

Malignant hypertension, and if it was scleroderma? Lessons from two cases. (PubMed, Blood Press) - "Treatment with high-dose ramipril led to a sustained recovery of kidney function, 221 μmol/L after five years)...When SRC is suspected, high-dose angiotensin-converting enzyme inhibitors (ACEi) should be initiated immediately, even before biopsy confirmation and continued despite initial kidney function decline. Early intervention is crucial for optimizing kidney outcomes and achieving effective blood pressure control."

Journal • Acute Kidney Injury • Cardiovascular • Hematological Disorders • Hypertension • Immunology • Nephrology • Pain • Renal Disease • Retinal Disorders • Scleroderma • Systemic Sclerosis

Ramipril ameliorates endometriosis by inducing oxidative stress-mediated apoptosis in the wistar rat. (PubMed, J Mol Histol) - "Furthermore, increased expression of Bax:Bcl-2 ratio (p < 0.001) and cleaved caspase-3 (p ≤ 0.0001) in ectopic lesions of group III was also observed. Administration of ramipril alone results in triggering oxidative stress mediated cleavage of PARP1, augmenting apoptosis in the ectopic lesions."

IO biomarker • Journal • Preclinical • Endometriosis • Gynecology • Inflammation • Women's Health • BAX • BCL2 • CASP3 • PCNA

Oral Ketone Beta-Hydroxybutyrate Supplement Retards the Loss of Glomerular Filtration Rate in Alport Mice on Dual RAS/SGLT2 Blockade. (PubMed, Kidney360) - "The results in mice suggest that beta hydroxybutyrate supplementation improves the GFR in Alport syndrome by suppressing inflammation and fibrosis. However, the effects did not lead to a significant increase in lifespan. Furthermore, the observed effects stay behind the effects of finerenone as a combination partner, which was tested earlier in the same mouse model."

Journal • Preclinical • Chronic Kidney Disease • Fibrosis • Genetic Disorders • Immunology • Inflammation • Nephrology • Renal Disease

Urine Measurements of the Renin-Angiotensin System-Regulated Proteins Predict Death and Graft Loss in Kidney Transplant Recipients Enrolled in a Ramipril versus Placebo Randomized Controlled Trial. (PubMed, J Proteome Res) - "A random forest classifier utilizing BST1 and LYPA1 peptides predicted death with an AUC of 0.80 (p = 0.0016). Urine measurements of RAS-regulated proteins may predict outcomes in kidney transplant recipients, although further prospective studies are required."

Journal • Fibrosis • Immunology • Transplantation • BST1 • LAMB2 • LAMC1

Ramipril, perindopril and trandolapril as potential chemosensitizers in ovarian cancer: considerations for drug repurposing. (PubMed, Drug Discov Today) - "Moreover, clinical data have shown that using ACE-Is with standard chemotherapy prolongs patient survival. Based on this rationale, we discuss the available in vitro models of OC for future studies with ACE-Is and demonstrate an in silico approach that has enabled us to select the most promising molecules: perindopril, ramipril, trandolapril and their diketopiperazine derivatives."

Journal • Review • Oncology • Ovarian Cancer • Solid Tumor

Complement-mediated TMA in a Patient with Scleroderma Renal Crisis (NKF-SCM 2025) - "Patient was started on captopril , then transitioned to ramipril. Additionally, we highlight the potential role steroids play in triggering SRC. Lastly, we acknowledge further study is needed to understand the pathogenesis and optimal management strategies for SRC and related TMA, for example the use of eculizumab in refractory cases."

Clinical • Acute Kidney Injury • Anemia • Antibody-mediated Rejection • Cardiovascular • Complement-mediated Rare Disorders • Fibromyalgia • Glomerulonephritis • Hematological Disorders • Human Immunodeficiency Virus • Hypertension • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Lupus Nephritis • Musculoskeletal Pain • Nephrology • Pain • Psoriasis • Psoriatic Arthritis • Renal Disease • Rheumatology • Scleroderma • Seronegative Spondyloarthropathies • Systemic Sclerosis • Thrombocytopenia • Thrombosis • Vasculitis

Explorative Study for Treating Persistent Developmental Stuttering with Ramipril (clinicaltrials.gov) - P3 | N=10 | Active, not recruiting | Sponsor: HaEmek Medical Center, Israel | Recruiting ➔ Active, not recruiting | Trial completion date: Nov 2023 ➔ Dec 2025 | Trial primary completion date: Jun 2023 ➔ Dec 2025

Enrollment closed • Trial completion date • Trial primary completion date

Chronic Kidney Disease Following Cardiac Arrest Manifesting as Dyspnoea and Peripheral Oedema in Cardiovascular Multimorbidity: Case Analysis and Brief Literature Review. (PubMed, In Vivo) - "This case highlights the importance of individualised treatment for patients with CKD alongside complex cardiovascular multi-morbidity. The administration of dapagliflozin and furosemide, together with careful adjustments to ramipril, were instrumental in stabilising the patient's renal function and alleviating symptoms. This case demonstrates how a multifaceted approach, continuous monitoring, and patient education are essential for achieving optimal outcomes in patients with CKD and cardiovascular comorbidities."

Journal • Review • Acute Kidney Injury • Asthma • Atrial Fibrillation • Cardiovascular • Chronic Kidney Disease • Coronary Artery Disease • Heart Failure • Hypertension • Immunology • Ischemic stroke • Myocardial Infarction • Nephrology • Pulmonary Disease • Renal Disease • Respiratory Diseases

Transcriptional modulation in Mediterranean Mussel Mytilus galloprovincialis following exposure to four pharmaceuticals widely distributed in coastal areas. (PubMed, Aquat Toxicol) - "This study investigates the impacts of Gemfibrozil, Metformin, Ramipril, and Venlafaxine, individually and combined on Mytilus galloprovincialis over 30 days and assesses persistent effects post-recovery using RNA-seq and 16S rRNA microbiota profiling. Notably, the up-regulation of mTOR1 signaling in all treatments after 30 days underscores its key role in coordinating bivalve stress responses. The Transcriptomic Hazard Index (THI) calculated for each treatment indicates major/severe hazards after exposure that decreased to slight/moderate hazards after depuration."

Journal

Increased anti-proteinuric effect of Lisinopril versus Ramipril in children with chronic kidney disease (IPNA 2025) - "No side effects were reported except for mild dizziness on Lisinopril in 1 patient. Conclusions Lisinopril should be preferred to Ramipril in patients with CKD on renoprotective treatment given its greater antiproteinuric effect in particular if long-term observation will document equal frequency and severity of adverse events."

Clinical • Chronic Kidney Disease • Focal Segmental Glomerulosclerosis • Genetic Disorders • Glomerulonephritis • IgA Nephropathy • Nephrology • Polycystic Kidney Disease • Renal Disease

Renovascular hypertension in 7-year-old girl: The importance of doppler ultrasound (IPNA 2025) - "Combined medication was introduced, consisting of propranolol, amlodipine, and ramipril. Fig.1: Color Doppler: increased velocity in the stenotic renal artery branch Conclusions Doppler ultrasound of kidney arteries is the first-choice investigation in hypertensive children to detect possible changes in blood flow spectrum. The arterial flow pattern in renal peripheral vessels, monitored by Doppler ultrasound, supports the diagnosis and follow-up of children with renovascular hypertension."

Cardiovascular • Hypertension • Nephrology • Pain • Pediatrics • Renal Disease

Combination therapy in arterial hypertension: how to personalize treatment (PubMed, G Ital Cardiol (Rome)) - "It is however necessary to underline that, among AT1 antagonists, the best scientific literature certainly supports the efficacy of candesartan (SCOPE, TROPHY, AMAZE, CALM and DIRECT studies) which should therefore be the reference molecule in clinical use. Therefore, the combinations of ramipril/amlodipine and candesartan/amlodipine represent a therapeutic opportunity of primary importance as they combine the ACE-inhibitor, AT1 antagonist and the calcium channel blocker with the best documentation of efficacy in randomized controlled trials.In conclusion, the support of the scientific literature indicates that the rational use of these combinations can certainly represent an optimal choice for the treatment of arterial hypertension according to the best criteria of therapeutic appropriateness."

Journal • Review • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension

Translational regulation of SND1 governs endothelial homeostasis during stress. (PubMed, J Clin Invest) - "In silico analysis of FDA-approved drugs led to the identification of an ACE inhibitor, ramipril, that protected against sunitinib-induced vascular dysfunction in vitro and in vivo, all while preserving the efficacy of cancer therapy. Our study established a central role for translational control of SND1 in sunitinib-induced endothelial dysfunction that could potentially be therapeutically targeted to reduce sunitinib-induced vascular toxicity."

Journal • Cardiovascular • Infectious Disease • Oncology • Targeted Protein Degradation • EIF4EBP1 • RNF168 • RNF8 • SND1

Physical Isolation Strategy in Multi-Layer Self-Nanoemulsifying Pellets: Improving Dissolution and Drug Loading Efficiency of Ramipril. (PubMed, J Pharm Sci) - "This study successfully developed and optimized ML-SNEP as a novel approach for enhancing the stability and release of RMP and THQ. The physical isolation strategy was a key approach in enhancing drug loading efficiency while preserving the advantageous dissolution properties of liquid SNEDDS. This approach offers valuable insights for developing advanced oral drug delivery systems for poorly water-soluble and labile drugs."

Journal

Clinical profile and treatment responses in C3 Glomerulonephritis: A case series (ISN-WCN 2025) - "Treatment regimens included cyclophosphamide with prednisolone for 3, mycophenolate mofetil (MMF) with prednisolone for 3, and prednisolone alone for 3 patients...All patients received maximally tolerated doses of ramipril...Standard treatments led to clinical improvement in a substantial number of patients, with only one patient progressed to ESKD. Therefore, early and individualized treatment approaches are crucial, as they can significantly enhance the outcomes for patients with C3GN."

Clinical • Cardiovascular • Complement-mediated Rare Disorders • Glomerulonephritis • Hypertension • Lupus Nephritis • Nephrology • Renal Disease

LONG TERM DISEASE REMISSION IN A CASE OF RAPIDLY PROGRESSIVE RENAL FAILURE DUE TO C3 GLOMERULONEPHRITIS (ISN-WCN 2025) - "Patient received prednisolone 1 m/kg/day, mycophenolate mofetil 500 mg twice daily, Ramipril 2.5 mg once a day. The C3 glomerulonephritis is a recently coined disease entity with variable natural history. It is a rare disease with minimum therapeutic options like eculizumab, plasma exchange or in few cases cyclophosphamide and ACE inhibitors. In this case report, we highlight a case scenario with complete and sustained disease remission with short course (6 months) of glucocorticoids and mycophenolate mofetil."

Clinical • ANCA Vasculitis • Anorexia • Cardiovascular • Complement-mediated Rare Disorders • Fatigue • Glomerulonephritis • Hepatology • Hypertension • IgA Nephropathy • Lupus Nephritis • Nephrology • Renal Disease • Vasculitis

CHALLENGES AND DILEMMA WITH RENAL TRANSPLANT IN AUTOSOMAL ALPORT SYNDROME AND ROLE OF NEXT GENERATION SEQUENCING, A CASE REPORT (ISN-WCN 2025) - "The renal transplant was performed with Basiliximab induction and showed excellent graft function with nadir creatinine of 0.9 mg/dl. The donor had a post-donation creatinine of 1 mg/dl and was put on low dose Ramipril to halt disease progression. Results Three year follow-up showed a creatinine of 1 mg/dl in both the renal transplant recipient and the donor.The family has been counseled regarding the regular follow ups and long-term outcome of the donor is to be ascertained. Conclusions Living-related renal transplant in autosomal AS is challenging and should be carried out after careful donor selection in consultation with genetic analysis."

Biomarker • Case report • Clinical • Next-generation sequencing • Chronic Kidney Disease • Genetic Disorders • Nephrology • Ophthalmology • Otorhinolaryngology • Transplantation